MAP1A

Across TCGA pan-cancer cohorts, MAP1A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP1A data layer compared with 26 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAP1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP1A expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where MAP1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.503	1.000	.006	14	view →
PDAC	OS	Median	III,IV	0.829	0.347	.006	13	view →
LUAD	DFS	Quartile	II,III,IV	0.738	1.000	.022	3	view →
CCRCC	OS	Tertile	II,III,IV	0.277	1.000	.024	2	view →
HNSC	DFS	Tertile	III,IV	0.908	0.728	.047	1	view →
GBM	DFS	Quartile	All	0.815	0.637	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP1A–LSCC (DFS)

Open the LSCC breakdown →